Myrio Therapeutics

Myrio Therapeutics is a privately-owned biotechnology company based in Melbourne, Australia, focused on revolutionizing immuno-oncology. The company has developed a proprietary antibody discovery platform called Retained Display (ReD), which enables the identification of high-affinity and selective antibodies against difficult-to-target proteins, including those expressed intracellularly (peptide-MHC complexes). Myrio's business model involves working with partners to develop therapeutics against specific targets while also establishing spin-outs or joint ventures to clinically develop specific assets. Their technology is designed to increase the number of addressable cancer and viral targets, supporting the development of various modalities including CAR-T cells, antibody-drug conjugates, and bispecific antibodies.